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ReviewGlossary
Adverse genome-modifying event (AGE): undesirable alteration(s) to the
cellular DNA or to the integrant structure resulting from a genome editing
(GE) intervention.
Ad.iting: designer nuclease-induced GE based on adenoviral vector donor DNA
templates.
Designer nuclease (DN): engineered sequence-specific biomolecules (also
known as programmable nucleases) consisting of nucleic acid binding and
cleaving domains. The most commonly used are ZFNs, TALENs, and RGNs.
Genome editing (GE): the purposeful manipulation of the DNA content of living
cells by adding to or removing from specific genomic sequences one or more
nucleotides.
GE fidelity: the level of integrant accurateness following a targeted genomic
DNA insertion event.
GE specificity: the relative frequencies of on-target versus off-target DN
chromosomal cleavage or exogenous DNA chromosomal insertion.
Homologous recombination (HR): cellular DNA break-repairing mechanism
involving the copying of genetic information from a donor DNA template (e.g.,
sister chromatid or homologous chromosome) whose sequence is identical
(homologous) to the acceptor, lesion-containing, chromosomal region. HR
occurs during the G2 and late S phases of the cell cycle and, in the presence of
exogenous donor DNA, can be exploited for introducing genomic changes with
nucleotide-level precision.
Integrant: exogenous DNA sequences once integrated in the genome of a
transfected or transduced cell.
Non-homologous end-joining (NHEJ): cellular DNA break-repairing mechan-
ism involving end-to-end ligation of DNA termini. NHEJ takes place throughout
the cell cycle and can be exploited for disrupting and restoring reading-framesGenome editing (GE) entails the modification of specific
genomic sequences in living cells for the purpose of
determining, changing, or expanding their function(s).
Typically, GE occurs after delivering sequence-specific
designer nucleases (e.g., ZFNs, TALENs, and CRISPR/
Cas9) and donor DNA constructs into target cells. These
designer nucleases can generate gene knockouts or
gene knock-ins when applied alone or in combination
with donor DNA templates, respectively. We review
progress in this field, with an emphasis on designer
nuclease and donor template delivery into mammalian
target cell populations. We also discuss the impact that
incremental improvements to these tools are having on
the specificity and fidelity attainable with state-of-the-
art DNA-editing procedures. Finally, we identify areas
that warrant further investigation.
Background and scope of GE
Genetic manipulation of higher eukaryote cells plays a
crucial role in basic and applied biology (Box 1). The advent
and recent diversification of designer nuclease (DN) tech-
nologies (see Glossary) and their combination with nucleic
acid and protein delivery systems have led to the emer-
gence of a new field interchangeably dubbed genome engi-
neering or GE. This biotechnology is becoming invaluable
to not only interrogate but also efficiently rewrite DNA
sequences in germ and somatic cells from an increasing
number of organisms, including those of mammals [1,2]. In-
deed, the universal role played by the genome in biological
systems opens up the possibility for adapting the basic
principles of GE to many disciplines and applications,
including gene therapy, functional genomics, regenerative
medicine, synthetic biology, and transgenesis.
Principles of DN-assisted GE
Various genetic engineering methodologies currently fall
under the operative definition of GE, such as those based
on site-specific recombinases (Box 2), single-stranded oligo-
deoxyribonucleotides (ssODNs), and recombinant adeno-as-
sociated viral vectors (rAAVs). However, we will focus on
reviewing the strategies, parameters, and outcomes of GE
procedures based on modifying target cell populations0167-7799/
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and versatile portfolio (Box 3). DNs are built to generate
double-stranded DNA breaks (DSBs) at predefined chromo-
somal positions and, in doing so, activate endogenous cellular
DNA repair pathways. Indeed, the two main DNA repair
pathways responsible for maintaining chromosomal integri-
ty, non-homologous end-joining (NHEJ) and homologous
recombination (HR), are activated by DSBs regardless of
whether these lesions occur in a random or a site-specific
fashion [3,4]. The repair of site-specific DSBs by NHEJ can
create knockouts of either coding or cis-acting, non-coding
sequences. These DSBs can also lead to knock-ins when
repaired by HR events involving surrogate DSB repair sub-
strates in the form of foreign donor DNA (Figure 1). Impor-
tantly, DNs can increase HR rates from 108 to 106 events
per treated cell to frequencies as high as 1–30%. These high
frequencies avoid the need for complex cell selection schemes
in many experimental settings broadening, as a result, the
applicability of HR-mediated GE.following DN-induced DSBs.
Protein transduction domain (PTD): a peptide (also known as a cell penetrating
peptide) whose net positive charge favors plasmalemma interactions and
ensuing cellular uptake of a linked cargo (normally a protein).
Transduction: the introduction of foreign nucleic acids into cells by means of
viral vector particles.
Transfection: the introduction of foreign nucleic acids into cells by means of
chemical or physical methods.
Box 1. Classical genome modification technologies
The genetic manipulation of mammalian cells can generically be
achieved by non-targeted and targeted chromosomal integration of
exogenously added recombinant DNA. The latter genetic engineering
procedures are preferable over the former because they result in
uniform transgene expression, owing to reduced chromosomal
positional effects and predictable phenotypes, owing to decreased
risk of endogenous gene disruption (i.e., insertional mutagenesis).
However, until the late 1990s the deployment of such precise genome
manipulations was restricted to particular HR-based experimental
systems, most notably to those involving the generation of knock-in
and knockout transgenic mice [99]. In these systems, the very low HR
rates and the high frequencies of random non-homologous chromo-
somal DNA insertions are circumvented by positive/negative selec-
tion regimens based on a combination of genetic tools and cytotoxic
drugs. These strategies are, however, often difficult to apply in other
biotechnological settings. Hence, early approaches aiming at genetic
modification of mammalian somatic cells exploited instead the
efficient, albeit non-targeted, chromosomal DNA integration capacity
of g-retroviral vectors (g-RVs) [100]. The g-RV-mediated genetic
modification of hematopoietic stem cells from boys afflicted by X-
linked severe combined immunodeficiency provided the first proof-
of-concept for gene therapy and, at the same time, materialized
genotoxicity risks in the form of leukemogenesis in some of the
treated patients [101]. These severe adverse events (SAEs) were
linked to the insertion of g-RV genomes carrying strong promoter/
enhancer elements in the vicinity of proto-oncogenes [100,101]. These
insertional mutagenesis findings initiated a trend towards HIV-1-
based lentiviral vectors (LVs) [102] and the use of self-inactivating
retroviral backbones in which viral regulatory sequences are replaced
by more physiological cellular promoters [100–102]. Of note, although
LVs also display a semi-random integration profile, their proviral
insertions are less biased towards the transcription start-sites of host
cell genes [103,104]. Furthermore, in contrast to g-RVs, LVs possess
active nuclear import mechanisms leading to efficient transduction of
non-cycling cells [105]. Although genotoxic risks associated with LV-
induced insertional mutagenesis remain [106], the aforementioned
tangible improvements led to therapeutic outcomes in Wiskott–
Aldrich syndrome and metachromatic leukodystrophy patients
[107,108]. An alternative DNA modification approach consists of
adapting transposon/transposase elements from vertebrate genomes.
In contrast to retroviral vectors, some of these genetic mobile
elements display a truly random chromosomal insertion profile – in
other words, do not show a preference for gene bodies and
associated regulatory sequences [109].
Review Trends in Biotechnology May 2015, Vol. 33, No. 5Although GE has a broad sphere of action in science and
technology, it will be most likely in the context of improved
gene therapies that GE interventions will be put to the test
in the most stringent manner, both in terms of their ultimate
efficiency and safety. An initial example of such ‘genome
surgery’, currently being tested in clinical trials, is based on
zinc-finger nuclease (ZFN)-mediated CCR5 (chemokine C-C
motif receptor 5) knockout to render CD4+T cells resistant to
HIV-1 infection [5]. In addition to acquired pathologies,
‘genome surgery’ is also being pursued and developed for
tackling inherited disorders. These include the geneticBox 2. Recombinase- and homing endonuclease-assisted
genome engineering
The high demand for controlled chromosomal DNA insertion in both
scientific and technological settings has been spurring the develop-
ment of different genome manipulation technologies. In addition to
artificial DNs, preeminent examples include the deployment of site-
specific recombinases and integrases (e.g., CRE, FLP, and fC31) [110],
adeno-associated virus (AAV) replicase/integrase complexes (i.e.,
Rep78/68) [111,112], and intron-encoded homing endonucleases
(HEs), also known as meganucleases (e.g., I-SceI) [113]. Although
these native proteins are limited to targeting fixed chromosomal
positions (e.g., fC31 and Rep78/68), and/or require the engineering of
their cognate recognition sequences into the target cell DNA in the
first place (e.g., CRE, FLP, and I-SceI), they have proved to be very
useful tools in particular biotechnology platforms and experimental
models. For instance, site-specific recombinases have been thor-
oughly used for setting up conditional gene activation/deletion
systems [110,114], whereas the I-SceI endonuclease has been
instrumental in DSB repair studies [3,4]. In fact, the latter studies
based on the generation of DSBs at specific model alleles and ensuing
activation of DNA repair pathways provided a strong rationale for the
development of sequence-tailored designer nucleases. This research,
initiated in the 1990s with the introduction of ZFNs [115], heralded the
beginning of the DN-assisted GE field. More recently, the tailoring of
site-specific recombinases and rare-cutting HEs to new predefined
target sequences is also underway. These technologies consist of
designing chimeric proteins formed by recombinase or HE domains
fused to DNA-binding motifs based on zinc-finger arrays or TALE
repeats [116]. In addition, strategies based on complex protein
engineering endeavors aiming at altering HE target-site preference
have equally been pursued [117].complementation or correction of faulty genes underlying
recessive disorders and the knockout of dominant illness-
associated alleles. Crucially, several aspects linked to GE
technologies require further investigation; these include
devising improved methods for delivering the often large
and complex GE tools as well as for increasing the specificity
and accuracy of the knock-in procedures.
Delivering the goods: introducing GE tools into target
cells
Introducing plasmids encoding DNs into target cell nuclei
by electroporation or by transfection based on liposome or
cationic polymer formulations are common and rapid pro-
cedures, applicable to complex somatic cell populations
[6,7]. Frequently, however, these methods are either inef-
ficient in primary cells, especially those that are quiescent
or slowly dividing, or lead to substantial cytotoxicity.
Therefore, approaches based on delivering DNs directly
as proteins or as in vitro-transcribed mRNA are being
investigated [8,9]. Advantages of protein and mRNA deliv-
ery include avoiding insertional mutagenesis risks and
lowering off-target effects owing to their shorter half-lives
relative to DNA. Related to this, DNs should ideally act in a
hit-and-run fashion, in other words generate site-specific
DSBs and decay (or cease being expressed) to minimize off-
target activities.
Transfection reagent-free strategies based on direct DN
delivery can capitalize on protein transduction domains
(PTDs) [8]. Genetic fusion of recombinant proteins to these
positively supercharged moieties favors their uptake by
cellular internalization mechanisms (e.g., lipid raft-depen-
dent macropinocytosis) [10]. There are, however, indica-
tions that it may be difficult to generate high yields of
soluble and active PTD-containing ZFNs [11,12], transcrip-
tion activator-like effector nucleases (TALENs) [13], or
Cas9 (CRISPR-associated 9) [14] proteins in Escherichia
coli. Alternative approaches are chemical conjugation of
DNs to PTDs, for direct plasmalemma penetration, or to
specific ligands, for receptor-mediated endocytosis. Indeed,281
Box 3. Characteristics and modus operandi of the main classes of DNs
ZFNs (Figure IA) are modular artificial proteins consisting of an array
of typically 4–6 synthetic Cys2-His2 zinc-finger motifs fused through a
linker to the catalytic domain of a restriction enzyme, traditionally that
of the type IIS endonuclease FokI (the recognition and cleavage DNA
sequences of type IIS restriction enzymes are non-overlapping).
Functional ZFNs consist of two monomers assembled in a tail-to-tail
orientation at the target site on opposite DNA strands. The local
dimerization of the FokI nuclease domains catalyzes upper and lower
strand DNA cleavage at a spacer sequence located between the ZFN
half-target sites. As a result, a site-specific DSB is formed.
TALENs (Figure IB) display an architecture generically similar to
that of ZFNs because the DNA-binding domain (DBD) is also fused via
a linker to the non-specific FokI nuclease domain that becomes
catalytically active upon in situ dimerization. For TALENs, however,
the DBD is derived from TALE proteins found in specific phytopatho-
genic bacteria (e.g., genus Xanthomomas) and comprises an array of
typically 15.5–19.5 repeat units of approximately 34 residues each.
The repeat residues at positions 12 and 13, called repeat-variable di-
residues (RVDs), dictate nucleotide recognition (e.g., RVDs NI, NG,
and HD recognize preferentially A, T, and C, respectively). Commonly
used TALEN scaffolds comprise 17.5 repeats per monomer and are
encoded by ORFs of approximately 3 kb.
RGNs (Figure IC) are RNA-dependent nucleases built on compo-
nents from clustered, regularly interspaced, short palindromic repeat
(CRISPR)-associated Cas systems evolved in bacteria and archaea as
immune mechanisms against foreign nucleic acids. The most
commonly used RGNs are based on the type II CRISPR-Cas9 nuclease
system from Streptococcus pyogenes. Cas9 is a large protein
(160 kDa) encoded by a 4.1 kb ORF and contains two nuclease
domains (RuvC and HNH). This nuclease is addressed to the target
site via its association with a single guide RNA (gRNA) molecule. The
gRNA component is a bipartite molecule engineered by fusing a
sequence-tailored CRISPR RNA (crRNA) to a scaffolding transactivat-
ing crRNA (tracrRNA). The target site consists of a nucleotide stretch
matching the 50 terminal gRNA sequence (usually 20 bp in length)
followed by a short nucleotide sequence called protospacer adjacent
motif (PAM; NGG, in the case of S. pyogenes Cas9). The fact that
target sequence specificity of RGNs is governed by RNA–DNA
hybridization, as opposed to protein–DNA interactions, confers
versatility and multiplexing capabilities to RGNs.
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Figure I. The main classes of DNs. (A) Zinc-finger nucleases (ZFNs). ZF, zinc-
finger; ZFN-L and ZFN-R, ‘left’ and ‘right’ ZFN monomers, respectively, bound to
their cognate half-target sites. (B) Transcription activator-like effector nucleases
(TALENs). TALEN-L and TALEN-R, ‘left’ and ‘right’ TALEN monomers,
respectively, bound to their cognate half target sites. (C) RNA-guided
nucleases (RGNs). The distribution of the nuclease motifs along the primary S.
pyogenes Cas9 protein sequence (upper panel) and schematics of a RGN
ribonucleoprotein complex bound to its target site (lower panel). Vertical
arrowheads mark the position at which the blunt-ended DSB is formed. PAM,
protospacer adjacent motif. Guide RNA, fusion product between crRNA and
tracrRNA moieties.
Review Trends in Biotechnology May 2015, Vol. 33, No. 5gene knockouts in cell lines were detected when using
TALENs whose exposed cysteine repeat residues were
conjugated to a poly-arginine moiety [13]. In another study,
ZFNs conjugated to transferrin were internalized via re-
ceptor-mediated endocytosis, and induced about 0.2% ho-
mology-directed gene repair of a defective reporter allele in
293 cells [15]. In other work, a cysteine-modified Cas9
nuclease conjugated to an artificial PTD was functional
when used in combination with a guide RNA (gRNA) bound
to another PTD via ionic interactions [14]. This methodol-
ogy led to CCR5 disruption in 8.4% of human fibroblasts
and 2.3% of ESCs. Interestingly, owing to the net positive
charge of their Cys2-His2 zinc-finger motifs, ZFNs display
an intrinsic cell penetrating capacity, which can lead to
targeted mutagenesis in a variety of cell types [11]. These
results are significant, considering the difficulties in pro-
ducing particular PTD-containing DNs.282Other DN delivery options under investigation include
protein transfection procedures. For instance, in vitro-
assembled Cas9:gRNA ribonucleoprotein complexes in-
duced about 20% targeted mutagenesis in human fibro-
blasts and ESCs following electroporation [16]. Of note,
compared to DNA, protein electroporation yielded approx-
imately twofold more alkaline phosphatase-positive colo-
nies (a marker of pluripotency), presumably reflecting a
lower cytotoxicity profile. In another study, enhanced GE
was achieved by combining cell cycle synchronization of
human cells with electroporation of ssODN donors and
Cas9:gRNA ribonucleoprotein complexes [17]. Chemical
transfection agents are also being investigated for direct
DN transfer. These agents might protect protein cargos
from serum inhibition or protease-mediated degradation
and, possibly, aid in endosomal escape. In this regard,
cationic lipids were successfully used to transfect Cas9.
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Figure 1. Illustration of the main GE strategies based on DNs. (A) NHEJ-mediated GE. Site-specific DSBs (cyan arrowheads) activate NHEJ repair pathways. These
processes can be exploited for obtaining different GE outcomes. Left panel, site-specific DSBs can yield reading-frame shifts resulting from indels (red boxes) that disrupt
and restore, respectively, in-frame and out-of-frame sequences. Middle panel, simultaneous induction of tandem DSBs by DN pairs (multiplexing) can result in the deletion
of the intervening sequence following end-to-end ligation of the distal chromosomal breakpoints. Alternatively, re-insertion of the intervening sequence in an ‘antisense’
orientation can also occur (not drawn). Of note, indel formation is, in this case, less likely because the newly formed junction (j) should yield a sequence that is not
susceptible to DN activity. Right panel, DN multiplexing applied to sequences in different chromosomes can be exploited for studying well-defined translocations. (B) HR-
mediated GE. Site-specific DSBs can also activate the HR pathway. In the presence of foreign DNA flanked by nucleotide sequences identical to those framing the target site
(donor DNA) the HR process yields well-defined junctions between the endogenous and the chromosomally integrated exogenous DNA. By using judiciously constructed
donor DNA templates, this DN-induced homology-directed gene targeting can be exploited to introduce or remove specific mutations or single-nucleotide polymorphisms
(asterisks) or, alternatively, insert a gene tag (not drawn), a complementary DNA (not drawn), or an entire transgene at a predefined chromosomal position (e.g., a ‘safe
harbor’ whose prototypic example is that of the AAVS1 locus on the human chromosome 19 at 19q13.42). Solid boxes and continuous lines represent exons and introns,
respectively. Abbreviations: AAVS1, adeno-associated virus integration site 1; DSB, double-stranded DNA break; DN, designer nuclease; GE, genome editing; HR,
homologous recombination; NHEJ, non-homologous end-joining.
Review Trends in Biotechnology May 2015, Vol. 33, No. 5To mimic the highly anionic nature of nucleic acids, Cas9
was either fused to a poly-anionic GFP or simply coupled to
its naturally negatively charged gRNA partner [18]. Albeit
with some cytotoxicity, this approach achieved up to 80%
targeted mutagenesis in an osteosarcoma reporter cell line.
In further experiments, ssODN-mediated gene repair and
in vivo gene disruption occurred at a frequency of approxi-
mately 8% in the reporter cell line and 20% in neonatal
mice, respectively [18].
As with DNA, mRNA transfer can be accomplished by
electroporation or by chemical transfection [19]. Electropo-
ration is gaining momentum, especially owing to its effi-
ciency in introducing synthetic mRNAs into specific
hematopoietic cell types [19]. In fact, a protocol combining
ZFN-encoding mRNA electroporation, integrase-defective
lentiviral vector (IDLV) donor DNA delivery, and stem cellviability-maintaining drugs provided a proof-of-principle
for gene targeting in CD34+ hematopoietic stem cells
[20]. Building upon these promising results, further stud-
ies are warranted to establish whether protein- and
mRNA-based GE methodologies can become streamlined
and broadly applicable, including in post-mitotic cells and
in conjunction with different gene knock-in systems.
Although viral vectors are generally less straightfor-
ward to produce than most non-viral delivery systems (Box
4), they constitute instrumental gene, and in some cases,
protein and mRNA transfer tools [21,22]. This is a conse-
quence of their unsurpassed efficiency in entering into
many cell types, both in vitro and in vivo. Therefore, the
ongoing adaptation of viral vectors to GE paradigms is
becoming natural and impactful. Indeed, they are suited
for many GE applications both dependent and independent283
Box 4. The structure of the main gene-editing viral vectors
LVs are made via transient transfection of producer cells (e.g., 293T) with
a mixture of recombinant lentiviral, packaging, and pseudotyping
plasmids. The recombinant vector contains, in addition to the transgenic
sequences, HIV cis-acting elements (i.e., 50 and 30 long terminal repeats,
packaging signal, Rev-responsive element, and a central polypurine
tract). The packaging and pseudotyping plasmids encode a minimal set
of primary HIV products (i.e., Gag, Pol, and Rev) and a heterologous
envelope protein (e.g., VSV-G), respectively. The latter moiety directs
vector particle–target cell interactions. The full-length genomic RNAs are
packaged in the nucleocapsids, which in turn become enveloped upon
budding from the producer cell membrane. The resulting vector particles
are subsequently collected from the producer cell supernatants and
purified. Crucially, for generating episomal IDLVs, the packaging
construct harbors specific point mutations in the pol region that yield
non-functional integrase moieties [118].
AdVs can be divided into helper-independent and helper-dependent
systems based on whether their production occurs in the absence or
presence, respectively, of a trans-complementing helper AdV vector
[119]. The former are deleted in one (first-generation) or more
(second-generation) early genes essential for in vitro replication
(i.e., E1, E2A, E2B, and E4); the latter wholly lack viral genes, and thus
contain from the parental virus genome exclusively the non-coding
cis-acting sequences involved in DNA replication and packaging (also
known as ‘gutless’ AdVs). The foreign DNA packaging capacities of
helper-independent and helper-dependent platforms range from 5–
8 kb to 37 kb, respectively. The generation of AdVs starts by
transfecting complementing packaging cell lines (e.g., 293, 911, or
PER.C6) with recombinant AdV DNA. The rescued AdV particles are
subsequently amplified through serial propagation in producer cells.
The resulting AdV preparations routinely reach high titers and display
high infectious/non-infectious particle ratios.
Normally, rAAV particles are assembled by transient transfection of
producer cells (e.g., 293T) with a rAAV plasmid mixed with constructs
expressing rep and cap (replication and packaging functions,
respectively) and specific adenoviral genes (helper functions)
[120]. Once in the cotransfected producer cells, the rAAV genomes,
whose structure consists of inverted terminal repeat (ITR)-flanked
transgene sequences, are excised from the plasmid backbone,
replicated, and packaged into pre-formed empty viral capsids. The
resulting rAAV particles are subsequently harvested and purified.
High-titer rAAV preparations can be made despite the fact that scale-
up of transient transfection procedures remains challenging with the
resulting stocks often containing low infectious/non-infectious parti-
cle ratios.
Review Trends in Biotechnology May 2015, Vol. 33, No. 5of targeting donor DNA. Because the ideal mode of opera-
tion for GE tools is via ‘hit-and-run’, episomal viral vectors
are often preferable over their chromosomally integrating
counterparts. Thus, IDLVs [20,23–29], baculoviral vectors
(BVs) [30–32], adenoviral vectors (AdVs) [5,28,33–43], and
rAAVs [44–51] are all being adapted for transducing DNs
and/or donor DNA into mammalian cells (Box 5).
So far, IDLVs have been mostly deployed for ZFN and/or
donor template transfer. Albeit involving different DN
delivery methods and target loci, the latter studies have
established IDLV donor DNA as a prolific HR substrate in
many cell types. For instance, gene knock-in frequencies of
approximately 3.5% in ESCs [23], 5% in lymphocytes [23],
and 9–40% in myoblasts [27,37] have been reported. Un-
fortunately, the optimal performance of IDLVs as a DN-
expressing platform is curtailed [52] due to the suscepti-
bility of IDLV genomes to epigenetic silencing phenomena
[53,54]. In addition, TALEN open reading frames (ORFs)Box 5. The viral vector concept and its main scaffolds
Viral vectors are built to exploit the refined cellular infection
mechanisms evolved by viruses for transferring their genomes into
host cell nuclei. In general, these mechanisms involve the binding of
virions to specific cell surface receptors, internalization, cytoplasmic
trafficking, and nuclear entry of the genetic material. Viral vectors are
in fact engineered viral particles whose genomes contain no or only a
subset of viral genes. This renders them replication-incompetent and,
simultaneously, creates space in their capsids and envelopes for the
packaging of exogenous nucleic acids. The retention of cis-acting
replication and encapsidation signals in viral vector genomes allows
their assembly in so-called packaging cells. These complementing
cell lines express in trans, either constitutively or transiently, the viral
functions for which the recombinant viral genomes are deleted. Often,
viral vectors are re-targeted to new cell types through the modifica-
tion (pseudotyping) of their capsids or envelopes. Importantly, viral
vectors have been under preclinical and clinical development for
many years as ‘classical’ gene therapy, oncolytic, or recombinant
vaccine agents. These efforts encompass vigorous testing and
regulatory history build-up. Such track-records bode well for the
implementation of viral vectors in GE-based translational research.
Lentiviral vectors (LVs), integrating or otherwise, are mostly based
on HIV-1 (Retroviridae family). This virus contains two ssRNA
284transduced by lentiviral systems suffer extensive deletions
due to reverse transcriptase template switching within
TALE repeats [34,55]. Importantly, this issue is not insur-
mountable because repetitive tract minimization via se-
quence recoding has permitted the transduction of not only
intact TALEN monomers but also ZFN dimers in single
lentiviral particles [29,55].
BVs have been tested in GE experiments involving the
delivery of donor DNA, ZFNs, and TALENs [30,31]. The
former experiments, deploying a GFP donor cassette,
achieved up to 4.4% CCR5-targeted cells in ESC cultures
[30]; the latter, using a 13.5 kb bicistronic donor cassette,
required drug selection to enrich for glioma cell popula-
tions containing 95% AAVS1-targeted cells [31]. The very
large packaging capacity of BV envelopes is being exploited
for expressing DN dimers from single viral constructs
[30,31]. As an instructive note, recent results have demon-
strated that, under particular BV propagation conditions,molecules (9.5 kb) packaged in a nucleocapsid shell surrounded by
a phospholipid envelope (120 nm). After host cell entry, triggered by
envelope glycoprotein–cell surface receptor interactions, the RNA
genome is converted en route to the nucleus into linear free-ended
double-stranded complementary DNA (cDNA) via virion-associated
reverse transcriptases. Next, the cDNA actively enters the nucleus via
its association with a karyophylic pre-integration complex. Finally,
proviruses are formed through integrase-dependent semi-random
host chromosomal DNA insertion [102].
Adenoviral vectors (AdVs) are derived from Adenoviridae family
members. Adenoviruses contain a linear, protein-capped, double-
stranded DNA genome (35–40 kb) packaged in an icosahedral
nonenveloped capsid (90–100 nm) that displays protruding recep-
tor-interacting fiber proteins [119].
Recombinant adeno-associated viral vectors (rAAVs) are derived
from Parvoviridae family members. Because AAVs depend on an
unrelated virus for replication (e.g., adenovirus), they are assigned to
the Dependovirus genus. These viruses have a linear ssDNA genome
(4.7 kb) with two ORFs (rep and cap) packaged in a fiberless
icosahedral non-enveloped capsid (20 nm). The coding sequences
are flanked by cis-acting inverted terminal repeats (ITRs), which can
form T-shaped secondary structures [120].
Review Trends in Biotechnology May 2015, Vol. 33, No. 5TALE repeats suffer rearrangements, presumably due to
the expression of recombination-enhancing factors in the
producer insect cells [32].
AdVs provide for an efficient and general platform for the
delivery of the main DN classes, namely, ZFNs [5,26,
28,33,42,43], TALENs [34,36,37,40,41,43], and RNA-guided
nucleases (RGNs) [35,37–40] both in vitro [5,26,28,33,
34,36,37,39,40,42,43] and in vivo [35,38,41]. The former stud-
ies included targeted mutagenesis in CD4+ T lymphocytes
[5,33], mesenchymal stromal cells [39], and keratinocytes
[28]; the latter encompassed modeling therapeutic and
oncogenic loss-of-function phenotypes in the liver [35,41]
and oncogenic chromosomal rearrangements in the lung
[38]. The versatility and relatively high genetic stability of
AdVs are also underscored by their capacity to co-transduce
dimers of ZFNs [5,26,33,42,43] and, in their helper-depen-
dent version (Box 4), TALENs [40,43]. The co-transduction
of RGN elements in single AdV particles has also been
demonstrated [35,38]. In addition, similarly to the aforemen-
tioned viral vectors, AdVs are also being explored for intro-
ducing donor HR substrates into DN-exposed target cells
[28,37,40,42].
rAAVs have served for delivering ZFNs and donor DNA
to target cells in vitro and in vivo [44–49]. The former
studies encompassed gene repair experiments at recombi-
nant target alleles in human cell lines and ESCs
[45,46,48,49]; the latter involved a proof-of-principle for
in vivo therapeutic GE by using hemophilia B murine
models [44,47]. More recently, rAAV technology was also
deployed for introducing RGN components into mice.
These experiments included loss-of-function studies to
investigate gene function in the mammalian brain and
to model lung cancer development [50,51]. Of note, the
versatility of the rAAV-RGN system is set to profit from
Cas9 variants (i.e., engineered or derived from orthogonal
species) whose smaller sizes bypass the limited AAV capsid
capacity issue.
Delivering predictability: improving DN specificity
DN specificity can vary greatly depending on the selected set
of reagents and experimental conditions. For instance, there
is evidence that short-term exposure of cells to DNs reduces
off-target activity and cytotoxicity [11,14,16,18,56], withBox 6. The GE landscape: a relationship among multiple factors
Exogenous template-independent targeted gene knockout (mutagen-
esis) strategies are based on the repair of site-specific DSBs by the
NHEJ pathway. The specificity of gene knockout strategies depends
on the ratio between on-target versus off-target DSB-forming events
resulting from DN activity. Off-target DSBs are undesirable in that
they induce unpredictable mutagenesis and can serve as deleterious
translocation-initiating substrates. On-target DSBs lead to the in-
tended targeted mutagenesis but can also serve as translocation-
initiating lesions. Exogenous template-dependent gene knock-in
(targeting) strategies are based on the repair of site-specific DSBs
by the HR pathway. The exogenously added donor DNA templates
bear sequence identity with the target site (HR substrates) and are
used as the source of new genetic information. The fidelity of gene
knock-in strategies depends on the generation of integrants whose
endogenous–exogenous DNA junctions are the result of HR events at
the target site. Both of these strategies rely on delivery systems for
introducing the different sets of GE tools (i.e., DNs or DNs plus donor
DNA) into the target cells. Regardless of the GE strategy, there areoff-target activity correlating with cytotoxicity [57]. Acute
cytotoxic effects may possibly result from ATM (ataxia
telangiectasia mutated)- or ATR (ATM- and RAD3-relat-
ed)-dependent protein kinase signaling pathway activation
leading to cell cycle arrest and apoptosis. This, together with
the potential involvement of off-target DSBs in generating
unintended mutations, ‘illegitimate’ recombination events,
and translocations, makes DN specificity a paramount pa-
rameter for advancing GE (Box 6). Therefore, the develop-
ment of DNs is often associated with considerable efforts
directed towards not only determining but also maximizing
their specificity.
Improved ZFN specificity has been achieved through
optimizing their DNA-binding domains (DBDs), nuclease
motifs, and intervening linker sequences. Regardless of the
DN platform, the DBD is clearly the major determinant
conferring on-target selectivity. In the case of ZFNs, DBD
assembly is complicated by the fact that interaction be-
tween each zinc-finger unit and its nucleotide triplet is
often affected by the surrounding context. Although some
of the various assembly platforms in use [58] take into
account this context-dependency, ZFN construction
remains difficult and time-consuming for non-experts. De-
spite this, zinc-finger assembly methods can be combined
with refinements to the FokI-derived nuclease domain.
Through cooperative dimerization, the native FokI enzyme
forms a catalytically active site at the nuclease domain
interface. In the context of ZFNs, dimerization involving
the same ZFN subunit can generate DSBs at sequences
recognized by such homodimers. To minimize this issue,
the dimerization interface of FokI cleavage domains has
been redesigned by site-directed mutagenesis to generate
obligate heterodimeric ZFN variants [59,60]. Rewardingly,
these variant pairs lead to a significant reduction in the
number of off-target cleavage events. Furthermore, the
inter-domain linker can also be optimized because its
composition and length influences ZFN activity and tar-
get-site selectivity [61,62].
The construction of functional TALENs is more
straightforward and predictable than that of ZFNs owing
to their direct repeat-to-nucleotide correspondence and
lower context-dependency. Moreover, besides displaying
wider genomic space coverage, TALENs present lowersometimes, in addition to the intended gene-modifying event,
stochastic AGEs either in the same cell or in other cells of the
population (Figure IA).
The ‘good’ integrants are on-target and contain exogenous DNA-
target site junctions formed by HR events; the ‘bad’ correspond to off-
target integrants; the ‘ugly’ contain one junction derived from
homology-directed gene targeting and another junction formed by
non-HR or ‘illegitimate’ recombination processes (e.g., NHEJ) invol-
ving on-target or off-target DSBs. The ‘bad’ and the ‘ugly’ integrant
forms can also include undefined tandem repeats formed by
exogenous DNA end-to-end ligations (concatemers) and delivery
vehicle-derived sequences (e.g., prokaryotic DNA and/or viral cis-
acting elements). These integrant forms contribute to reducing the
uniformity of transgene expression in genome-modified cell popula-
tions and hindering the restoration of endogenous reading frames
following gene targeting and gene repair approaches (Figure IB).
The relative weight given to the ‘efficiency’, ‘specificity’, and ‘fidelity’
of GE procedures is in a trend towards equilibrium (Figure IC).
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Figure I. The GE landscape. (A) From strategies to outcomes. (B) Intended and deviant GE-derived integrants. (C) The evolving Zeitgeist regarding the three principal GE parameters.
Review Trends in Biotechnology May 2015, Vol. 33, No. 5off-target activity and cytotoxicity in human cells, as
revealed in side-by-side comparisons with ZFNs [63]. Be-
cause TALENs and ZFNs share a similar general architec-
ture (Box 3), approaches to improve the already high286specificity profile of TALENs are in some cases reminiscent
of those applied to ZFNs. These strategies include coupling
the DBDs of TALEN pairs to obligate heterodimeric FokI
motifs [64] and hybrid monomeric DNA-binding proteins
Review Trends in Biotechnology May 2015, Vol. 33, No. 5consisting of TALE repeats fused to homing endonuclease
domains [65,66]. The specificity of TALENs is also being
improved via optimizing the TALEN terminal domains as
well as the length and composition of TALE arrays [67–69].
Initial studies on the specificity profile of RGNs in target
cell populations indicated substantial rates of off-target
mutagenesis [70–73]. Of note, more recent experiments
based on whole-genome sequencing of individual clones
derived from RGN-modified pluripotent stem cells (PSCs)
point towards rare RGN off-target activity at the single cell
level [40,74,75]. Hitherto, the specificity of RGNs has been
enhanced in three principal ways: (i) using paired Cas9
‘nickases’ to make targeted DSBs through cooperative
offset nicks on opposite DNA strands [76,77], (ii) using
truncated gRNAs for fine-tuning gRNA–DNA binding en-
ergies [78], and (iii) using catalytically inactive Cas9 fused
to FokI nuclease domains to induce DSBs through cooper-
ative binding of such fusion products [79,80]. Furthermore,
deploying orthogonal Cas9 variants [81] that recognize
different protospacer adjacent motif (PAM) sequences is
yet another promising strategy for enhancing the RGN
specificity profile.
Regardless of the DN platform, readily available and
plentiful bioinformatics tools can greatly aid target site
selection in the context of complex genomic sequences to
judiciously reduce off-target DNA cleavage. Of note, be-
yond primary target sequence selection, the impact epige-
netically regulated chromatin conformations have on the
overall specificity and activity of DNs remains poorly
understood. Finally, the in-depth characterization of the
specificity profile of the various DN platforms will require
the implementation of unbiased genome-wide and sensi-
tive methods for tracing off-target events in treated cells
[24,82–84].
Delivering precision: improving GE fidelity
The depicted sought-after GE outcomes (Figure 1) are often
compounded by collateral adverse genome-modifying events
(AGEs) (Box 6). In this regard, the DN-induced gene knock-
in strategies are particularly multifaceted because their
ultimate performance depends not only on DN efficiency
and specificity but also on the frequency and fidelity with
which the exogenous DNA is inserted at the target site. The
deviant GE outcomes impacting the fidelity of DN-induced
gene knock-in procedures are manifold. For instance, AGEs
can result from the engagement of donor DNA not only with
DN-induced off-target DSBs but also with breakage-prone
fragile sites and DSBs created by DNA metabolic processes
or environmental mutagens. Most notably, next to precise
genome-modifying events, random insertions and targeted
single-copy or concatemeric insertions generated through
non-homologous recombination processes (e.g., NHEJ) can
occur. Although targeted, the ‘ugly’ integrant fraction (Box
6) introduces disruptive delivery vehicle-derived backbone
sequences (e.g., viral or bacterial DNA) into the cellular
DNA. Moreover, in DN-exposed cell populations, a sizable
fraction of target alleles will undergo gene disruption in-
stead of homology-directed gene targeting. This stems from
the fact that NHEJ occurs throughout the cell cycle and
competes with HR for DSB repair [85]. Finally, targeted
DSBs can lead to translocations involving not only ectopicbut also allelic chromosomal sequences, as recently demon-
strated [82].
The discovery that ssDNA breaks (nicks), albeit to a
lesser extent than DSBs, trigger HR at recombinant and
endogenous loci in mammalian cells [86–88] has provided a
strong rationale for developing nicking versions of DNs.
Indeed, the fact that nicks are normally not engaged by
NHEJ makes such ‘nickases’ promising tools for increasing
the overall precision of GE. Examples include developing
mutant DN scaffolds [89–91] and engineered DBDs fused
to heterologous sequence- and strand-specific cleaving
motifs (e.g., Tev-I or MutH) [92,93].
The GE ‘fidelity’ parameter is expected to start receiving
higher scrutiny and emphasis in the near future (Box 6).
Indeed, high-fidelity GE will be instrumental for ‘genome
surgery’ interventions and basic research (e.g., repairing
defective genes and generating isogenic lines to unambig-
uously establish genotype–phenotype relationships, re-
spectively). Therefore, the nature and structure of the
donor DNA component is set to play a paramount role.
Early studies showed that both linear and supercoiled
plasmid conformations are prone to ‘illegitimate’ recombi-
nation processes resulting in random chromosomal inser-
tion and concatemerization [94]. These events can further
be compounded by the incorporation of immunogenic and
silencing-prone prokaryotic sequences [37]. In line with
this, recent experiments targeting different loci in PSCs
subjected to TALEN and donor plasmid transfections
revealed that cellular fractions harboring random inte-
grants were large, constituting in some cases the majority
of the genome-modified population [95].
In settings compatible with small exogenous DNA inser-
tions (e.g., point-mutation addition or removal), delivery of
ssODNs offers a simpler and faster alternative to plasmid-
and viral vector-borne donor DNA [17,18,55,96,97]. The
first experiments combining DN and ssODNs resulted in
0.16% faithful repair of a defective EGFP allele in 293 cells
following ZFN delivery. Similar levels were obtained with
a control double-stranded plasmid [97]. Unfortunately, the
majority of ssODN-modified cells harbored low-fidelity
integrants represented by donor DNA capture and internal
mutations. A subsequent study using panels of ZFNs and
target cell lines demonstrated high-efficiency ssODN-
based GE, with a ssODN yielding twofold higher GE levels
than a corresponding plasmid substrate. Furthermore, this
work also demonstrated that the single-stranded character
of these templates reduces donor DNA capture at site-
specific DSBs. Of note, however, DNA sequencing did
reveal unintended mutations within ssODN-derived inte-
grants [96]. Whether these mutations are the result of
ssODN synthesis errors or are instead caused by intracel-
lular DNA repairing processes requires further investiga-
tion. More recently, ssODN-based GE has been expanded
to include the use of TALENs and RGNs [17,18,55].
Although IDLV genomes serve as efficient substrates
for DN-assisted GE [23–25,27–29], a sizable proportion
of the chromosomally integrated exogenous DNA repre-
sents inaccurate integrants which, among others, include
off-targeted and concatemeric DNA forms. These frac-
tions, which in some cases can be as high as 5–40%
[24,37], are presumably generated by non-HR events287
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Figure 2. Grading of GE precision resulting from DNs and donor DNA templates with different specificity- and fidelity-imparting features. ‘Sloppy’ nucleases inducing high
rates of off-target cleavage and donor DNA templates with free-ended termini yield the highest frequencies of adverse genome-modifying events (AGEs) (Level I). AGEs
include mutagenesis and translocations caused by ‘illegitimate’ recombination-mediated repair of induced chromosomal breaks, concatemeric integrant forms, off-target
integrants, and on-target integrants with undefined structures (e.g., formed by NHEJ) and/or with unwarranted composition (e.g., delivery vehicle-derived sequences).
Conversely, highly-specific nucleases generating low rates of off-target cleavage and end-protected donor DNA templates yield the lowest frequencies of AGEs (Level IV).
Intermediate levels of AGEs follow from using free-ended donor DNA and highly-specific nucleases (Level II), and from deploying end-protected donor DNA together with
‘sloppy’ nucleases (Level III). Shaded DNA forms indicate their relative lower frequencies in genome-modified cell populations. Upward and downward vertical arrows
represent high and low rates, respectively, of mutations and translocations involving off-target DSBs. Abbreviations: DSB, double-stranded DNA break; GE, genome editing;
NHEJ, non-homologous end-joining.
Review Trends in Biotechnology May 2015, Vol. 33, No. 5involving end-to-end ligation of IDLV genomes to each
other or to site-specific and sporadic chromosomal DSBs.
This picture is generally recapitulated in DSB-induced
gene targeting of rAAV donor DNA, which shares with
IDLV free-ended linear genomes [47,49].
Conversely, although the absolute frequencies of AdV
donor DNA-modified cells are significantly lower than those
obtained with IDLV, detailed side-by-side clonal analyses
revealed that the vast majority of AdV-modified cells un-
dergo proper GE [37] – that is, they harbor targeted and
single-copy integrants whose chromosomal junctions result
from bona fide HR events at both ends (Box 6). This finding of
scarless DN-induced AdV DNA editing (‘Ad.iting’, in short)
could be attributed to the capping of linear AdV genomes by
covalently attached terminal proteins [37]. These protein-
DNA structures presumably hinder, either in a steric or
biochemical manner, ‘illegitimate’ recombination-mediated
joining of vector genomes with each other and with sponta-
neous or off-target chromosomal DSBs. It is enticing to
speculate a parallel operational role between the sheltered288telomeric ends of linear eukaryotic chromosomes [98] and
the end-protected linear AdV genomes in preventing their
DNA termini from degradation and inappropriate recombi-
nation. Hence, DNs and donor DNA structures both contrib-
ute decisively to the ultimate precision of the GE process
(Figure 2). Whether protein–DNA structures other than
those of AdV genomes will also yield high-fidelity GE awaits
further investigation.
Concluding remarks and future perspectives
The relative emphases given to the efficiency, specificity,
and fidelity of GE are changing. The earlier focus on
achieving meaningful levels of GE tool delivery and ensu-
ing GE efficiency is being complemented by the relatively
more recent efforts in improving the specificity of DNs and
the precision with which exogenous DNA becomes incor-
porated at genomic target sequences. The prolific and
rapidly emerging research lines reviewed in this work
are systematically addressing these complementary pa-
rameters, which together underlie robust and accurate
Review Trends in Biotechnology May 2015, Vol. 33, No. 5GE. This trend is expected to continue gathering momen-
tum and, considering the multifaceted nature of GE, be
grounded on a wide range of disciplines and scientific
insights.
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